Published in PLoS One on April 23, 2008
Dose-Finding Study of E7070 in Combination With Irinotecan | NCT00060567
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma | NCT00002907
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer | NCT00039455
Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems. PLoS One (2010) 0.94
Degeneracy as a substrate for respiratory regulation. Respir Physiol Neurobiol (2010) 0.88
Ensembles of signal transduction models using Pareto Optimal Ensemble Techniques (POETs). Biotechnol J (2010) 0.86
Modeling and analysis of retinoic acid induced differentiation of uncommitted precursor cells. Integr Biol (Camb) (2011) 0.85
Modeling and analysis of the molecular basis of pain in sensory neurons. PLoS One (2009) 0.84
Impact of flow on ligand-mediated bacterial flocculation. Math Biosci (2013) 0.83
Heterogeneous dynamics, robustness/fragility trade-offs, and the eradication of the macroparasitic disease, lymphatic filariasis. BMC Med (2016) 0.81
Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature (2002) 45.19
Transcriptional regulatory networks in Saccharomyces cerevisiae. Science (2002) 43.52
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Cancer cell cycles. Science (1996) 21.29
Cyclin is degraded by the ubiquitin pathway. Nature (1991) 17.93
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Robustness in bacterial chemotaxis. Nature (1999) 12.55
Biological robustness. Nat Rev Genet (2004) 9.98
The generalisation of student's problems when several different population variances are involved. Biometrika (1947) 9.40
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Universally sloppy parameter sensitivities in systems biology models. PLoS Comput Biol (2007) 7.89
Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem (1983) 7.03
Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer (2006) 6.76
Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature (2005) 6.69
Robustness of cellular functions. Cell (2004) 6.65
Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol (1995) 6.41
Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science (1992) 6.40
Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell (1995) 6.08
Reverse engineering of biological complexity. Science (2002) 6.06
The two-hybrid system: an assay for protein-protein interactions. Trends Genet (1994) 5.06
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet (2003) 4.74
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature (1996) 4.05
The anaphase-promoting complex: it's not just for mitosis any more. Genes Dev (2002) 3.89
Complexity and robustness. Proc Natl Acad Sci U S A (2002) 3.88
CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer (2007) 3.46
Bow ties, metabolism and disease. Trends Biotechnol (2004) 3.28
Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov (2006) 3.27
A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov (2007) 3.22
Untangling the wires: a strategy to trace functional interactions in signaling and gene networks. Proc Natl Acad Sci U S A (2002) 3.18
Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev (1997) 3.02
Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol (2005) 3.02
Rescue of cyclin D1 deficiency by knockin cyclin E. Cell (1999) 2.54
Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Mol Cell Biol (1996) 2.44
Development of mice expressing a single D-type cyclin. Genes Dev (2002) 2.43
Robustness properties of circadian clock architectures. Proc Natl Acad Sci U S A (2004) 2.31
A benchmark for methods in reverse engineering and model discrimination: problem formulation and solutions. Genome Res (2004) 2.06
A model for restriction point control of the mammalian cell cycle. J Theor Biol (2004) 1.86
The anaphase-promoting complex: a key factor in the regulation of cell cycle. Oncogene (2005) 1.85
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A (1997) 1.81
Iterative approach to model identification of biological networks. BMC Bioinformatics (2005) 1.80
Deregulation of cyclin E in breast cancer. Oncogene (1995) 1.78
Sensitivity analysis of discrete stochastic systems. Biophys J (2005) 1.70
Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res (1998) 1.65
High-throughput screening for protein-protein interactions using two-hybrid assay. Methods Enzymol (2000) 1.64
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs (1999) 1.63
Regulation of the mammalian cell cycle: a model of the G1-to-S transition. Am J Physiol Cell Physiol (2002) 1.58
Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol (2001) 1.58
Cyclin D1 and human neoplasia. Mol Pathol (1998) 1.50
Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) (1984) 1.44
Model identification of signal transduction networks from data using a state regulator problem. Syst Biol (Stevenage) (2005) 1.39
Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol (2007) 1.33
Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer (1997) 1.33
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res (2005) 1.32
Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol (1983) 1.32
Robustness properties of apoptosis models with respect to parameter variations and intrinsic noise. Syst Biol (Stevenage) (2005) 1.28
A quantitative analysis of the kinetics of the G(2) DNA damage checkpoint system. Proc Natl Acad Sci U S A (1999) 1.28
Intracellular protein interaction mapping with FRET hybrids. Proc Natl Acad Sci U S A (2006) 1.24
The kinetic origins of the restriction point in the mammalian cell cycle. Cell Prolif (1999) 1.23
Sensitivity analysis of intracellular signaling pathway kinetics predicts targets for stem cell fate control. PLoS Comput Biol (2007) 1.22
Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res (1992) 1.21
Isochron-based phase response analysis of circadian rhythms. Biophys J (2006) 1.06
PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther (2006) 1.02
Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res (1995) 1.00
Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol (1998) 1.00
Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression. J Biol Chem (2003) 0.92
Instabilities in phosphorylation-dephosphorylation cascades and cell cycle checkpoints. Oncogene (1999) 0.91
Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Mol Cancer Ther (2005) 0.89
Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res (2000) 0.87
Missing the target: ubiquitin ligase drugs stall. J Natl Cancer Inst (2005) 0.87
Phase sensitivity analysis of circadian rhythm entrainment. J Biol Rhythms (2007) 0.85
Evolutionary design on a budget: robustness and optimality of bacteriophage T7. Syst Biol (Stevenage) (2006) 0.83
Inhibition of puromycin-induced apoptosis in breast cancer cells by IGF-I occurs simultaneously with increased protein synthesis. Neoplasma (2004) 0.83
E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anticancer Drugs (2002) 0.77
Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model. Leukemia (2007) 0.75
A review of the mammalian unfolded protein response. Biotechnol Bioeng (2011) 1.83
Engineering the spatial organization of metabolic enzymes: mimicking nature's synergy. Curr Opin Biotechnol (2008) 1.76
Constructing hierarchical spheres from large ultrathin anatase TiO2 nanosheets with nearly 100% exposed (001) facets for fast reversible lithium storage. J Am Chem Soc (2010) 1.45
Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol (2007) 1.33
Graphene-supported anatase TiO2 nanosheets for fast lithium storage. Chem Commun (Camb) (2011) 1.15
Fast formation of SnO2 nanoboxes with enhanced lithium storage capability. J Am Chem Soc (2011) 1.13
Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model. J Biomed Mater Res A (2013) 0.95
Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems. PLoS One (2010) 0.94
Interferon regulatory factor-1 binds c-Cbl, enhances mitogen activated protein kinase signaling and promotes retinoic acid-induced differentiation of HL-60 human myelo-monoblastic leukemia cells. Leuk Lymphoma (2011) 0.92
α-Fe2O3 nanotubes with superior lithium storage capability. Chem Commun (Camb) (2011) 0.91
Multiscale models of breast cancer progression. Ann Biomed Eng (2012) 0.91
Ensembles of signal transduction models using Pareto Optimal Ensemble Techniques (POETs). Biotechnol J (2010) 0.86
SnO2 nanosheets grown on graphene sheets with enhanced lithium storage properties. Chem Commun (Camb) (2011) 0.85
Modeling and analysis of retinoic acid induced differentiation of uncommitted precursor cells. Integr Biol (Camb) (2011) 0.85
Engineering nonspherical hollow structures with complex interiors by template-engaged redox etching. J Am Chem Soc (2010) 0.85
The Src-family kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant myeloblastic leukemia cells. PLoS One (2013) 0.82
Ensembles of uncertain mathematical models can identify network response to therapeutic interventions. Mol Biosyst (2010) 0.82
Cybernetic model predictive control of a continuous bioreactor with cell recycle. Biotechnol Prog (2003) 0.80
Computational modeling and analysis of insulin induced eukaryotic translation initiation. PLoS Comput Biol (2011) 0.80
Stochastic reaction-diffusion simulation of enzyme compartmentalization reveals improved catalytic efficiency for a synthetic metabolic pathway. Metab Eng (2007) 0.80
Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells. Leuk Lymphoma (2010) 0.79
Ubiquibodies, synthetic E3 ubiquitin ligases endowed with unnatural substrate specificity for targeted protein silencing. J Biol Chem (2014) 0.79
TiO2 and SnO2@TiO2 hollow spheres assembled from anatase TiO2 nanosheets with enhanced lithium storage properties. Chem Commun (Camb) (2010) 0.77
Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin. Thromb Res (2009) 0.76
Hierarchical approaches for systems modeling in cardiac development. Wiley Interdiscip Rev Syst Biol Med (2013) 0.75